Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

B-cell receptor pathway inhibitors (BCRis) have transformed treatment of chronic lymphocytic leukemia (CLL); however, the efficacy of therapies for patients whose disease is refractory to/relapses after (R/R) BCRis is unknown. Venetoclax is a selective, orally bioavailable BCL-2 inhibitor with activ...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood
Auteurs principaux: Coutre, Steven, Choi, Michael, Furman, Richard R., Eradat, Herbert, Heffner, Leonard, Jones, Jeffrey A., Chyla, Brenda, Zhou, Lang, Agarwal, Suresh, Waskiewicz, Tina, Verdugo, Maria, Humerickhouse, Rod A., Potluri, Jalaja, Wierda, William G., Davids, Matthew S.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2018
Sujets:
Clinical Trials And Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5922273/
https://ncbi.nlm.nih.gov/pubmed/29305552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-06-788133
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires